This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics StockThe Motley Fool • 08/14/24
Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock SurgesBenzinga • 08/09/24
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024GlobeNewsWire • 08/08/24
Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024GlobeNewsWire • 07/29/24
Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For Its Newly Approved Skin Cancer Cell TherapyBenzinga • 07/29/24
Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced MelanomaGlobeNewsWire • 06/28/24